Brazil Greenlights Five New Injectable Diabetes Drugs
14 Articles
14 Articles
Brazil greenlights five new injectable diabetes drugs - Regional Media News
By Luciana Magalhaes SAO PAULO, July 29 (Reuters) - Brazil's health regulator Anvisa on Wednesday said it approved five new injectable GLP-1 drugs for diabetes and obesity treatment, capitalizing on a wave of expedited regulatory reviews following the expiration of Ozempic's patent in the country in March. The newly authorized medications - Owozy, Seemasun, Zempneo, Semavy, and Orsema - all use synthetically obtained semaglutide as their active …
The National Agency of Health Surveillance approved, on Wednesday, five new semiglutide-based pens in Brazil after the end of the patent of the molecule in the country. All received the endorsement for the treatment of type 2 diabetes, with doses of up to 1.34 mg/mL. In all, six medicines of the type have been released by the health agency since the end of the license, in March. The approved pens were: Semavy - from Cosmed Cosmetics and Medicine…
Medscape
WTVBBrazil Greenlights Five New Injectable Diabetes Drugs
Brazil's health regulator said it approved five new injectable GLP-1 drugs for diabetes and obesity treatment, following the expiration of Ozempic’s patent in the country. Reuters Health Information
The National Agency for Health Surveillance (Anvisa) has granted the registration for five new injectable medicines, popularly known as weight loss tablets, this Wednesday, July 29, 2026. All devices use semaglutide obtained by synthetic means as an active principle and are indicated for the treatment of adult patients with type 2 diabetes mellitus. [...]
Sun Pharma receives approval to manufacture and market semaglutide in Brazil
Sun Pharmaceutical Industries announced that it has received approval from the Brazilian Health Regulatory Agency, ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Sun Pharma plans to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil. It will be a…
The National Agency for Health Surveillance (Anvisa) approved the registration of five new semiglutide pens, indicated for the treatment of adult patients with type 2 diabetes mellitus, without sufficient control. Popularly, these medicines are called weight loss pens because they help in weight loss. They are: Owozy - registration granted to the company Avita Care Importation and Distribution of Products Ltda. (CNPJ no. 31.203.582/0001-37) Seem…
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
